trial summary · NCT07698535
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
Dynamic Assessments of Molecular Response to Guide Early 177Lu-PSMA-617 Treatment Discontinuation: The DYNAMO Study
Trial record from the TrialBase DB dataset, status RECRUITING, condition Metastatic Castration-Resistant Prostate Adenocarcinoma, sponsored by University of Washington. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) in patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for the disease to grow, spread, or get worse or come back after a period of improvement. ctDNA TF is a type of ctDNA measurement. Research has shown ctDNA TF may be a promising way to predict which patients will respond to 177Lu-PSMA-617 treatment. Measuring ctDNA TF may help doctors identify which patients may benefit from changing treatments sooner, which may be an effective way to guide early 177Lu-PSMA-617 treatment discontinuation in patients with metastatic castration-resistant prostate cancer.
Source record: https://clinicaltrials.gov/study/NCT07698535
Facts
| registry id | NCT07698535 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Metastatic Castration-Resistant Prostate Adenocarcinoma |
| sponsor | University of Washington |
| sponsor class | OTHER |
| enrollment | 64 |
| start date | 2026-11-15 |
| primary completion | 2029-07-05 |
| completion | 2029-07-05 |
| results posted | not reported |
Conditions
- Metastatic Castration-Resistant Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
- Lutetium Lu 177 Vipivotide Tetraxetan
- Cell-free Circulating Tumor DNA Assay
- Computed Tomography
- Docetaxel
- PSMA PET Scan
- Single Photon Tomography and Computed Tomography Scan
- Biospecimen Collection
Countries
- United States
Intervention types: DRUG, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.